Neuroendocrinology
Regulation of Hypothalamic Neurons
Long-Term Changes in Gastrin, Cholecystokinin and Insulin in Response to Oxytocin TreatmentPetersson M.a,b · Hulting A.-L.a · Andersson R.b · Uvnäs-Moberg K.b,caDepartment of Molecular Medicine, Karolinska Hospital, Stockholm; bDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm; cDepartment of Animal Physiology, Swedish University of Agricultural Sciences, Uppsala, Sweden
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: March 19, 1999
Issue release date: March 1999
Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Abstract
The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose. Since oxytocin may enhance the activity of centrally located α2-adrenoreceptors, a second aim of this study was to explore whether these receptors are involved in the effects. For this purpose, oxytocin (1.0 mg/kg) or NaCl was given subcutaneously (s.c.) once a day during 5 days to male rats. Rats were decapitated 1, 3 and 10 days after the last injection, blood was collected and hormone levels were radioimmunoassayed. The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment. Gastrin levels were decreased on day 1, 3 and 10 (ANOVA; p < 0.01). In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05). When the α2-adrenoreceptor agonist clonidine (2.5 µg/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only. No change in glucose or somatostatin levels was found in response to the oxytocin treatment. In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels. These effects may be mediated by changes in vagal nerve activity.
Related Articles:
References
- Buijs RM: Vasopressin and oxytocin: Their role in neurotransmission. Pharmacol Ther 1983;22:127–141.
- Sawchenko PE, Swanson LW: Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol 1982;205:260–272.
- Björkstrand E, Eriksson M, Uvnäs-Moberg K: Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Neuroendocrinology 1996;63:377–383.
- Björkstrand E, Ahlenius S, Smedh U, Uvnäs-Moberg K: The oxytocin receptor antagonist 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin inhibits effects of the 5HT1A receptor antagonist 8-OH-DPAT on plasma levels of insulin, cholecystokinin and somatostatin. Regul Pept 1996;63:47–52.
- Uvnäs-Moberg K: Role of efferent and afferent vagal nerve activity during reproduction: Integrating function of oxytocin on metabolism and behaviour. Psychoneuroendocrinology 1994;19:687–695.
- Siaud P, Puech R, Assenmacher I, Alonso G: Microinjection of oxytocin into the dorsal vagal complex decreases pancreatic insulin secretion. Brain Res 1991;546:190–194.
- Petersson M, Alster P, Lundeberg T, Uvnäs-Moberg K: Oxytocin causes a long-term decrease of blood pressure in female and male rats. Physiol Behav 1996;60:1311–1315.
- Petersson M, Alster P, Lundeberg T, Uvnäs-Moberg K: Oxytocin increases nociceptive thresholds in a long-term perspective in female and male rats. Neurosci Lett 1996;212:87–90.
- Uvnäs-Moberg K, Alster P, Petersson M: Dissociation of oxytocin effects on body weight in two variants of female Sprague-Dawley rats. Integr Physiol Behav Sci 1996;31:44–55.
- Petersson M, Uvnäs-Moberg K, Erhardt S, Engberg G: Oxytocin increases locus coeruleus alpha-2-adrenoreceptor responsiveness. Neurosci Lett 1998;255:115–118.
- Linden A, Carlqvist M, Hansen S, Uvnäs-Moberg K: Plasma concentrations of cholecystokinin, CCK-8, and CCK-33,39 in rats, determined by a method based on enzyme digestion of gastrin before HPLC and RIA detection of CCK. Gut 1989;30:213–222.
- Marchini G, Lagercrantz H, Uvnäs-Moberg K: Plasma gastrin in newborn infants and their relationship to catecholamines. J Dev Physiol 1990;14:147–155.
- Efendic S, Nylén A, Roovete A, Uvnäs-Wallensten K: Effects of glucose and arginine on the release of immunoreactive somatostatin from the isolated perfused rat pancreas. FEBS Lett 1978;92:33–35.
-
Tribollet E, Barberis C, Jard S, Elands J, Dubois-Dauphin M, Marguerat A, Dreifuss JJ: Mapping and analysis of receptors for neurohypophyseal peptides present in the brain; in Pickering BR, Wakerley JB, Summerlee AJS (eds): Neurosecretion: Cellular Aspects of the Production and Release of Neuropeptides. New York, Plenum, 1988, pp 81–89.
- Charpak S, Armstrong WE, Mühletaler M, Dreifuss JJ: Stimulatory action of oxytocin on neurones of the dorsal motor nucleus of the vagus nerve. Brain Res 1984;300:83–89.
- Dreifuss JJ, Raggenbass M, Charpak S, Dubois-Dauphin M, Tribollet E: A role of central oxytocin in autonomic functions: Its action in the motor nucleus of the vagus nerve. Brain Res Bull 1988;20:765–770.
-
Rogers RC, Herman GE: Dorsal medullary oxytocin, vasopressin, oxytocin antagonist and TRH effects on gastric acid secretion and heart rate. Peptides 1985;6:1142–1148.
- Siaud P, Puech R, Assenmacher I, Alonso G: Adrenergic innervation of the dorsal vagal motor nucleus: possible involvement in inhibitory control of gastric acid and pancreatic insulin secretion. Cell Tissue Res 1990;259:535–542.
- Hancock MB, Nicholas AP: Oxytocin immunoreactive projections onto medullary adrenaline neurons. Brain Res Bull 1987;18:213–219.
- Linden A, Eriksson M, Hansen S, Uvnäs-Moberg K: Suckling-induced release of cholecystokinin into plasma in the lactating rat: Effects of abdominal vagotomy and lesions of central pathways concerned with milk ejection. J Endocrinol 1990;127:257–263.
- Jones PM, Robinson IC: Differential clearance of neurophysin and neurohypophyseal peptides from the cerebrospinal fluid in conscious guinea pigs. Neuroendocrinology 1982;34:297–302.
- Moos F, Freund-Mercier MJ, Guerné U, Guerné JM, Stoeckel ME, Richard Ph: Release of oxytocin and vasopressin by magnocellular nuclei in vitro: specific facilitatory effect of oxytocin on its own release. J Endocrinol 1984;102:63–72.
- Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P: The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol 1989;162:1–9.
-
Uvnäs-Moberg K: Release of gastrointestinal peptides in response to vagal activation by electrical stimulation, feeding and suckling; in Kral JG, Powley TL, Brooks C (eds): Vagal Nerve Function. Amsterdam, Elsevier, 1983, pp 141–155.
- Uvnäs-Moberg K, Lundeberg T, Bruzelius G, Alster P: Vagally mediated release of gastrin and cholecystokinin following sensory stimulation. Acta Physiol Scand 1992;146:349–356.
Article / Publication Details
Published online: March 19, 1999
Issue release date: March 1999
Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
